🫸🏻 在Welcome Party之後，本屆BTBA的第一個實體月會即將到來！🫷
本次月會為Data-Driven Decision Making in Biotech/Healthcare的職涯分享。在數據滿街的世界，如何有效蒐集、整合、分析以及利用龐大資料至關重要。生技相關產業中，除了利用機器學習/AI加速藥物開發之外，其他部門對於應用數據以及數位工具來做方案決策也越加重視。
我們邀請Paul Lo, Georgia Lin, 以及Chun Liu分享他們在Biotech/Healthcare業界的工作經歷，內容跨足大藥廠的portfolio策略 、臨床試驗中數位工具的應用，以及藥局行銷活動的效度評估等。無論您是正擁有轉換跑道的念頭，或是想在目前的職位上探索新的斜槓人生，相信本次的月會討論能夠讓大家更加了解生技產業中的不同面向！(P.S. 本活動全程以中文進行; In-person only)
https://www.linkedin.com/in/ying-chih-paul-lo-md-phd-3b696059/
Dr. Ying-Chih (Paul) Lo is a distinguished nephrologist with both MD and PhD in Biomedical Informatics from National Yang Ming University, Taiwan. He currently serves as the Associate Director of Portfolio Data Science and Advanced Analytics at Novartis. Prior to venturing into the pharmaceutical industry, Dr. Lo dedicated nearly four years to postdoctoral research at Brigham and Women’s Hospital and Harvard Medical School. His extensive expertise in medical AI research spans a broad spectrum, encompassing predictive modeling, computer vision, and natural language processing. Dr. Lo is deeply passionate about harnessing the power of informatics and data science to advance health-related applications.
https://www.linkedin.com/in/georgia-lin-pmp/
Georgia Lin is an experienced project manager in research, biotech, and medical devices. Her background includes lab management, operations, and biomarker development at BlueBird Bio. Since joining Takeda in 2021, she specializes in digital strategy for clinical trials and digital health product development, promoting cross-functional collaboration for streamlined processes. Georgia holds BSc and MSc degrees in Medical Lab Science, Pathology, and Nutrition & Metabolism.
https://www.linkedin.com/in/chia-hsing-pi-13a29490/
Chia-Hsing is a seasoned scientist with extensive process development experience in cell and gene therapy. He has deep knowledge of applying Quality by Design (QbD) and has been involved in multiple end-to-end autologous and allogeneic cell therapies such as iPSC-derived neurology, cardiology, and neurology as well as ex vivo gene therapies from early to late phases. He holds his M.S. and Ph.D. from the University of Pennsylvania and the University of Minnesota - Twin Cities, respectively.